surrogate virus neutralization test cpass Search Results


90
GenScript corporation cpass surrogate virus neutralization test (svnt)
Spearman’s correlation analysis of serum anti-receptor-binding domain (anti-RBD) antibody titers and neutralizing activity in 70 participants in the study (22 vaccinated with BNT162b2, 9 with mRNA-1273, 27 with ChAdOx1 nCov19, 9 with Ad26.COV2.S, 1 COVID-19 convalescent, and 2 with mixed vaccines). (A) Correlation plot of anti-RBD antibody titers versus neutralizing activity (percentage inhibition of RBD-ACE2 binding) assessed through the <t>cPass™</t> ELISA-based assay. (B) Correlation plot of anti-RBD antibody titers versus neutralizing activity assessed through IgG/Neutralizing Antibody Rapid Test. (C) Correlation plot of neutralizing activity evaluated through cPass™ ELISA-based assay and IgG/Neutralizing Antibody Rapid Test cassettes. Trendlines, Spearman’s r , and p -values are also represented (statistical significance for p < 0.05).
Cpass Surrogate Virus Neutralization Test (Svnt), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpass surrogate virus neutralization test (svnt)/product/GenScript corporation
Average 90 stars, based on 1 article reviews
cpass surrogate virus neutralization test (svnt) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Spearman’s correlation analysis of serum anti-receptor-binding domain (anti-RBD) antibody titers and neutralizing activity in 70 participants in the study (22 vaccinated with BNT162b2, 9 with mRNA-1273, 27 with ChAdOx1 nCov19, 9 with Ad26.COV2.S, 1 COVID-19 convalescent, and 2 with mixed vaccines). (A) Correlation plot of anti-RBD antibody titers versus neutralizing activity (percentage inhibition of RBD-ACE2 binding) assessed through the cPass™ ELISA-based assay. (B) Correlation plot of anti-RBD antibody titers versus neutralizing activity assessed through IgG/Neutralizing Antibody Rapid Test. (C) Correlation plot of neutralizing activity evaluated through cPass™ ELISA-based assay and IgG/Neutralizing Antibody Rapid Test cassettes. Trendlines, Spearman’s r , and p -values are also represented (statistical significance for p < 0.05).

Journal: Frontiers in Immunology

Article Title: Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy

doi: 10.3389/fimmu.2022.833085

Figure Lengend Snippet: Spearman’s correlation analysis of serum anti-receptor-binding domain (anti-RBD) antibody titers and neutralizing activity in 70 participants in the study (22 vaccinated with BNT162b2, 9 with mRNA-1273, 27 with ChAdOx1 nCov19, 9 with Ad26.COV2.S, 1 COVID-19 convalescent, and 2 with mixed vaccines). (A) Correlation plot of anti-RBD antibody titers versus neutralizing activity (percentage inhibition of RBD-ACE2 binding) assessed through the cPass™ ELISA-based assay. (B) Correlation plot of anti-RBD antibody titers versus neutralizing activity assessed through IgG/Neutralizing Antibody Rapid Test. (C) Correlation plot of neutralizing activity evaluated through cPass™ ELISA-based assay and IgG/Neutralizing Antibody Rapid Test cassettes. Trendlines, Spearman’s r , and p -values are also represented (statistical significance for p < 0.05).

Article Snippet: Some of them have high costs, require trained personnel, and can only be carried out in a Biosafety Safety Level 3-equipped laboratory, whereas others, such as the cPass surrogate virus neutralization test (sVNT) (GenScript, Piscataway, NJ, USA) used in this work, are ELISA-based assays and only require optical density readers.

Techniques: Binding Assay, Activity Assay, Vaccines, Inhibition, Enzyme-linked Immunosorbent Assay

Neutralizing activity evaluated by cPass™ ELISA-based SARS-CoV-2 Neutralization Antibody Detection Kit in 70 sera from differently vaccinated individuals. Serum samples were considered positive when ≥30% inhibition was measured, as shown by the red line in the graph. (A) Percentage inhibition of receptor-binding domain–angiotensin-converting enzyme 2 (RBD-ACE2) binding within different vaccination groups (see also <xref ref-type= Table 3 ). Statistical significance was assessed by ANOVA following Tukey’s multiple comparisons test, ** p < 0.005, * p < 0.05. (B) Comparison of neutralizing activity in sera from individuals who received adenoviral DNA-based vaccines and mRNA-based vaccines. Statistical significance was assessed by unpaired t-test, * p = 0.0016. " width="100%" height="100%">

Journal: Frontiers in Immunology

Article Title: Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy

doi: 10.3389/fimmu.2022.833085

Figure Lengend Snippet: Neutralizing activity evaluated by cPass™ ELISA-based SARS-CoV-2 Neutralization Antibody Detection Kit in 70 sera from differently vaccinated individuals. Serum samples were considered positive when ≥30% inhibition was measured, as shown by the red line in the graph. (A) Percentage inhibition of receptor-binding domain–angiotensin-converting enzyme 2 (RBD-ACE2) binding within different vaccination groups (see also Table 3 ). Statistical significance was assessed by ANOVA following Tukey’s multiple comparisons test, ** p < 0.005, * p < 0.05. (B) Comparison of neutralizing activity in sera from individuals who received adenoviral DNA-based vaccines and mRNA-based vaccines. Statistical significance was assessed by unpaired t-test, * p = 0.0016.

Article Snippet: Some of them have high costs, require trained personnel, and can only be carried out in a Biosafety Safety Level 3-equipped laboratory, whereas others, such as the cPass surrogate virus neutralization test (sVNT) (GenScript, Piscataway, NJ, USA) used in this work, are ELISA-based assays and only require optical density readers.

Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay, Neutralization, Inhibition, Binding Assay, Comparison, Vaccines

Mean neutralizing activity measured by the  cPass™  ELISA-based assay in sera from 70 individuals who received different vaccines.

Journal: Frontiers in Immunology

Article Title: Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy

doi: 10.3389/fimmu.2022.833085

Figure Lengend Snippet: Mean neutralizing activity measured by the cPass™ ELISA-based assay in sera from 70 individuals who received different vaccines.

Article Snippet: Some of them have high costs, require trained personnel, and can only be carried out in a Biosafety Safety Level 3-equipped laboratory, whereas others, such as the cPass surrogate virus neutralization test (sVNT) (GenScript, Piscataway, NJ, USA) used in this work, are ELISA-based assays and only require optical density readers.

Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay, Vaccines